Changes of T-lymphocyte subpopulation and differential expression pattern of the T-bet and GATA-3 genes in diffuse large B-cell lymphoma patients after chemotherapy

Cancer Cell International

Yongping Song¹  Xudong Wei¹  Yufu Li¹  Ruihua Mi¹  Qianyu Li¹  Lin Chen¹  Qingsong Yin¹ 

[1] Henan Cancer Hospital, Henan Institute of Hematology, and Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

关键词: Immunoregulation;    GATA-3;    T-bet;    Th1/Th2;    Diffuse large B cell lymphoma;   

Others  :  1230695
DOI  :  10.1186/s12935-014-0085-9

 received in 2014-02-13, accepted in 2014-08-12,  发布年份 2014

【 摘 要 】

Background and objective

T cell-mediated immunity plays an important role in enhancing antitumor response.This study aimed to investigate the changes in the T-lymphocyte subpopulation and to characterize the differential expression pattern of corresponding regulatory genes in peripheral blood mononuclear cells (PBMCs) from diffuse large B cell lymphoma (DLBCL) patients before and after chemotherapy.

Methods

A total of 56 DLBCL patients were recruited for analysis of T-cell subset distribution in the peripheral blood using flow cytometry; serum interferon (IFN)-γ and interleukin (IL)-4 levels using enzyme-linked immunosorbent assays; and early growth response protein 1 (EGR-1), T-bet, GATA-binding protein 3 (GATA-3), and transforming growth factor (TGF)-β mRNA levels using quantitative reverse-transcription polymerase chain reaction. Twenty-six healthy subjects served as controls.

Results

The percentage of CD3⁺CD4⁺T lymphocytes in peripheral blood from DLBCL patients was significantly decreased, whereas the percentages of CD3⁺CD8⁺T and CD4⁺CD25⁺T cells were significantly increased compared to those in controls (p < 0.05). Serum levels of IFN-γ and IL-4 were also significantly lower in DLBCL patients than those in controls (p < 0.05), and the levels of EGR-1, T-bet, and GATA-3 mRNA in PBMCs were lower (2.69 ± 1.48, 9.43 ± 2.14, and 20.83 ± 9.05 fold, respectively) in DLBCL patients than those in controls. Furthermore, there was a positive association between the levels of EGR-1 and T-bet mRNA (p = 0.001). However, the level of TGF-β mRNA was significantly increased in DLBCL patients, which was inversely associated with the T-bet mRNA level (p = 0.008), but positively associated with the percentage of T regulatory cells in PBMCs (p = 0.011). After three cycles of chemotherapy, the distribution of T-lymphocyte subsets in DLBCL patients were changed, and the levels of EGR-1, T-bet, and GATA-3 mRNA were significantly increased (p < 0.05) compared to those before chemotherapy.

Conclusions

These results demonstrate the changes in T-lymphocyte subpopulations and the altered expression 34 pattern of the corresponding regulatory genes in PBMCs from DLBCL patients after chemotherapy, which are associated with the response of patients to treatment. The preferential expression of the T-bet gene after chemotherapy was closely correlated with the increased expression of the EGR-1 gene and decreased expression of the TGF-β gene.

【 授权许可】

   
2014 Yin et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, Monnereau A, Maynadié M, Chiu BC, Marcos-Gragera R, Costantini AS, Cerhan JR, Weisenburger DD: InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010, 116(20):e90-e98. doi:10.1182/blood-2010-06-289561
• [2]Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013, 381(9880):1817-1826. doi:10.1016/S0140-6736(13)60313-X
• [3]Simard JF, Baecklund F, Chang ET, Baecklund E, Hjalgrim H, −OlovAdami H, Glimelius B, Smedby KE: Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes. Int J Cancer 2013, 132(11):2659-2666. doi:10.1002/ijc.27944
• [4]Grulich AE, Vajdic CM, Cozen W: Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007, 16(3):405-408.
• [5]Li YQ: T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting. J Hematol Oncol 2012, 5(Suppl 1):A3. doi:10.1186/ 1756-8722-5-S1-A3 BioMed Central Full Text
• [6]Komeno Y, Kitaura J, Watanabe-Okochi N, Kato N, Oki T, Nakahara F, Harada Y, Harada H, Shinkura R, Nagaoka H, Hayashi Y, Honjo T, Kitamura T: AID-induced T-lymphoma or B-leukemia/lymphoma in a mouse BMT model. Leukemia 2010, 24(5):1018-1024. doi:10.1038/leu.2010.40
• [7]Park SR: Activation-induced cytidine deaminase in B cell immunity and cancers. Immune Netw 2012, 12(6):230-239. doi:10.4110/in.2012.12.6.230
• [8]Inaoka RJ, Jungbluth AA, Gnjatic S, Ritter E, Hanson NC, Frosina D, Tassello J, Etto LY, Bortoluzzo AB, Alves AC, Colleoni GW: Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients. Cancer Immunol Immunother 2012, 61(12):2207-2214. doi:10.1007/s00262-012-1285-6
• [9]Afshar-Sterle S, Zotos D, Bernard NJ, Scherger AK, Rödling L, Alsop AE, Walker J, Masson F, Belz GT, Corcoran LM, O’Reilly LA, Strasser A, Smyth MJ, Johnstone R, Tarlinton DM, Nutt SL, Kallies A: Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 2014, 20(3):283-290. doi:10.1038/nm.3442
• [10]Danielou-Lazareth A, Henry G, Geromin D, Khaznadar Z, Briere J, Tamouza R, Cayuela JM, Thieblemont C, Toubert A, Dulphy N: At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. Eur J Immunol 2013, 43(5):1383-1388. doi:10.1002/eji.201242733
• [11]Yin QS, Yang LJ, Chen SH, Zhou YB, Wu XL, Li YQ: Generation of diffuse large B cell lymphoma-associated antigen-specific Valpha6/Vbeta13 + T cells by TCR gene transfer. J Hematol Oncol 2011, 4:2. doi:10.1186/ 1756-8722-4-2 BioMed Central Full Text
• [12]Yin QS, Tan H, Chen S, Yang LJ, Ye JM, Li YQ: Charaterization of conserved CDR3 sequence of TCR α- and β-chain genes in peripheral blood T-cells from patients with diffuse large B-cell lymphoma. Hematology 2010, 15(1):48-57. doi:10.1179/ 102453310X12583 347009694
• [13]Yin QS, Wei XD, Wang XJ, Mi RH, Lv XD, Wang Q, Zhao HF, Li YF, Song YP: Clinical significence of dynamic monitoring of thymic recent output function in different stages of treatment in patients with diffuse large B-cell lymphoma. Chin J Hematol 2013, 32(1):55-59.
• [14]Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 2005, 175(1):5-14.
• [15]Zhu JF, Paul WE: CD4 T cells: fates, functions, and faults. Blood 2008, 112(5):1557-1569.
• [16]Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100(6):655-669.
• [17]Szabo SJ, Sullivan BM, Peng SL, Glimcher LH: Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003, 21:713-758.
• [18]Kaplan MH, Schindler U, Smiley ST, Grusby MJ: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996, 4(3):313-319.
• [19]Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126(6):1121-1133.
• [20]Mantel PY, Schmidt-Weber CB: Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol 2011, 677:303-338.
• [21]Oestreich KJ, Weinmann AS: Transcriptional mechanisms that regulate T helper 1 cell differentiation. Curr Opin Immunol 2012, 24(2):191-195. doi:10.1016/j.coi.2011.12.004
• [22]Pai SY, Kang BY, Sabadini AM, Parisini E, Truitt ML, Ho IC: Distinct structural requirements of GATA-3 for the regulation of thymocyte and Th2 cell differentiation. J Immunol 2008, 180(2):1050-1059.
• [23]Carleton M, Haks MC, Smeele SA, Jones A, Belkowski SM, Berger MA, Linsley P, Kruisbeek AM, Wiest DL: Early growth response transcription factors are required for development of CD4-CD8- thymocytes to the CD4+CD8+ stage. J Immunol 2002, 168(4):1649-1658.
• [24]Boone DN, Qi Y, Li Z, Hann SR: Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci U S A 2011, 108(2):632-637. doi:10.1073/pnas.1008848108
• [25]Zhang HH, Chen XJ, Wang JK, Guang WH, Han W, Zhang H, Tan X, Gu Y: EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression. Sci Rep 2014, 4:5416. doi:10.1038/srep05416
• [26]Gatter K, Pezzella F: Diffuse large B-cell lymphoma. Diagn Histopathol 2010, 16(2):69-81.
• [27]Yin QS, Wei XD, Wang XJ, Mi RH, Wang Q, Zhao HF, Zhang CJ, Li YF, Song YP: Dynamic monitoring of the T cell subpopulations diffuse large B-cell lymphoma patients with distinct gene subtypes. Leuk Lymphoma 2013, 22(3):145-147.
• [28]Le Souëf PN: Gene-environmental interaction in the development of atopic asthma: new developments. Curr Opin Allergy Clin Immunol 2009, 9(2):123-127. doi:10.1097/ACI. 0b013e3283292283
• [29]Kawashima M, Miossec P: mRNA quantification of T-bet, GATA-3, IFN-γ, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J Clin Immunol 2005, 25(3):209-214.
• [30]Solomou EE, Keyvanfar K, Young NS: T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 2006, 107(10):3983-3991.
• [31]Bowen H, Kelly A, Lee T, Lavender P: Control of cytokine gene transcription in Th1 and Th2 cells. Clin Exp Allergy 2008, 38(9):1422-1431. doi:10.1111/j.1365-2222. 2008.03067.x
• [32]Chang CF, D’Souza WN, Ch’en IL, Pages G, Pouyssegur J, Hedrick SM: Polar opposites: Erk direction of CD4 T cell subsets. J Immunol 2012, 189(2):721-731. doi:10.4049/ jimmunol.1103015
• [33]Shin HJ, Lee JB, Park SH, Chang J, Lee CW: T-bet expression is regulated by EGR1-mediated signaling in activated T cells. Clin Immunol 2009, 131(3):385-394. doi:10.1016/j.clim.2009.02.009
• [34]Gordon KJ, Blobe GC: Role of transforming growth factor-beta superfamily signaling pathways in human disease. Bichim Biophys Acta 2008, 1782:197-228.
• [35]Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A: Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol 2013, 6:50. doi:10.1186/1756-8722-6-50 BioMed Central Full Text
• [36]Alshaker HA, Matalka KZ: IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int 2011, 11:33. doi:10.1186/1475-2867-11-33 BioMed Central Full Text
• [37]Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO: T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 2011, 35(1):123-134. doi:10.1016/j.immuni.2011.04.019
• [38]Luo XR, Zhang Q, Liu V, Xia ZB, Pothoven KL, Lee C: Cutting Edge: TGF-β-Induced Expression of Foxp3 in T cells is Mediated through Inactivation of ERK. J Immunol 2008, 180(5):2757-2761.
• [39]Kanhere A, Hertweck A, Bhatia U, Gökmen MR, Perucha E, Jackson I, Lord GM, Jenner RG: T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat Commun 2012, 3:1268. doi:10.1038/ncomms 2260
• [40]Stams WAG, den Boer ML, Beverloo HB, Meijerink JPP, Stigter RL, van Wering ER, Janka-Schaub GE, Slater R, Pieters R: Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21) + pediatric ALL. Blood 2003, 101(7):2743-2747. doi:10.1182/blood-2002-08-2446
• [41]Zha X, Yan X, Shen Q, Zhang Y, Wu X, Chen S, Li B, Yang L, Geng S, Weng J, Du X, Li Y: Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia. J Hematol Oncol 2012, 5:74. doi:10.1186/1756-8722-5-74 BioMed Central Full Text
• [42]Shi L, Chen S, Lu Y, Wang X, Xu L, Zhang F, Yang L, Wu X, Li B, Li Y: Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML. Cancer Cell Int 2013, 13(1):37. doi:10.1186/1475-2867-13-37 BioMed Central Full Text